Premium
The clinical spectrum of missense mutations of the first aspartic acid of cbEGF‐like domains in fibrillin‐1 including a recessive family
Author(s) -
HilhorstHofstee Yvonne,
Rijlaarsdam Marry EB,
Scholte Arthur JHA,
Swartvan den Berg Marietta,
Versteegh Michel IM,
van der Schootvan Velzen Iris,
Schäbitz HansJoachim,
Bijlsma Emilia K,
Baars Marieke J,
KerstjensFrederikse Wilhelmina S,
Giltay Jacques C,
Hamel Ben C,
Breuning Martijn H,
Pals Gerard
Publication year - 2010
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.21372
Subject(s) - missense mutation , fibrillin , haploinsufficiency , biology , genetics , phenotype , mutation , marfan syndrome , mutant , aspartic acid , gene , amino acid , medicine
Abstract Marfan syndrome (MFS) is a dominant disorder with a recognizable phenotype. In most patients with the classical phenotype mutations are found in the fibrillin‐1 gene ( FBN1 ) on chromosome 15q21. It is thought that most mutations act in a dominant negative way or through haploinsufficiency. In 9 index cases referred for MFS we detected heterozygous missense mutations in FBN1 predicted to substitute the first aspartic acid of different calcium‐binding Epidermal Growth Factor‐like (cbEGF) fibrillin‐1 domains. A similar mutation was found in homozygous state in 3 cases in a large consanguineous family. Heterozygous carriers of this mutation had no major skeletal, cardiovascular or ophthalmological features of MFS. In the literature 14 other heterozygous missense mutations are described leading to the substitution of the first aspartic acid of a cbEGF domain and resulting in a Marfan phenotype. Our data show that the phenotypic effect of aspartic acid substitutions in the first position of a cbEGF domain can range from asymptomatic to a severe neonatal phenotype. The recessive nature with reduced expression of FBN1 in one of the families suggests a threshold model combined with a mild functional defect of this specific mutation. © 2010 Wiley‐Liss, Inc.